Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. - Brodowicz, T; Lang, I; Kahan, Z; Greil, R; Beslija, S; Stemmer, S M; Kaufman, B; Petruzelka, L; Eniu, A; Anghel, R; Koynov, K; Vrbanec, D; et al. (British Journal of Cancer, 2014)